Antonio Passaro, Medical Oncologist and a Medical Director with High Specialization Assignment at the European Institute of Oncology, shared a post on LinkedIn:
“I am honoured to be recognised for the scientific impact in medical oncology of lung cancer over the last five years, ranked 19th worldwide and 1st in Italy, within a list that includes true giants of the field such as Martin Reck, Peters Solange, Tony Mok, and many other friends and colleagues, is not something to be read as a simple position in a ranking (ScholarGPS methodology).
It is a quantitative assessment that integrates productivity, quality, and impact, focusing on what truly matters: how much research shapes knowledge and translates into clinical practice.
This journey is inseparable from the ecosystem that made it possible.
The IEO Istituto Europeo di Oncologia has always believed in clinical research, multidisciplinarity, and international ambition as core pillars of lung cancer care.
My deepest gratitude goes to the leadership that has built and continues to guide this vision, particularly Lorenzo Spaggiari and Filippo de Marinis.
Working alongside them, growing the Lung Cancer Programme day by day, and pushing its clinical and scientific boundaries forward is both an honour and an ever-increasing challenge.
Being an active part of this process, at this level and at this moment, gives meaning to the daily and continuous work of the past ten years.
With gratitude to the institution, the teams, the colleagues, and above all the patients who make all of this possible.”
Learn more about the recognition.
More posts featuring Antonio Passaro.